2022 World Conference on Lung Cancer (ePosters)-EP08.02-034. OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L

EP08.02-034. OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L

Back to course

Pdf Summary

The OCELOT study aims to evaluate the efficacy and safety of osimertinib as a third-line treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC) following first-line treatment with osimertinib and second-line treatment with platinum-pemetrexed chemotherapy. Osimertinib has been established as the standard of care for EGFR-mutated NSCLC in the first-line setting. However, there is limited data on its effectiveness in the third-line setting.<br /><br />Previous studies have shown that cytotoxic chemotherapy after first-line EGFR-TKI, a longer duration between initial and rechallenge EGFR-TKI, response to first-line EGFR-TKI, and absence of the T790M mutation are predictors for the success of EGFR-TKI rechallenge. However, these studies have used earlier generation EGFR-TKIs that are not effective against T790M resistance mutations.<br /><br />The OCELOT study will enroll patients with common EGFR mutations at the time of second-line platinum-pemetrexed chemotherapy or at the time of third-line osimertinib rechallenge. The study will also enroll patients with atypical EGFR mutations in the first-line setting to assess the efficacy of osimertinib in this population.<br /><br />The primary objective of the study is to assess the objective response rate (ORR) of third-line osimertinib in patients with common EGFR mutations. Secondary objectives include assessing progression-free survival, duration of response, disease control rate, tumor shrinkage, overall survival, and time to treatment failure. Safety/toxicity and health-related quality of life will also be evaluated.<br /><br />For patients with atypical EGFR mutations, the study aims to determine the ORR, progression-free survival, duration of response, disease control rate, tumor shrinkage, overall survival, and time to treatment failure for both first-line and third-line treatment with osimertinib.<br /><br />Overall, the OCELOT study will provide important information on the efficacy and safety of osimertinib as a third-line treatment for EGFR-mutated NSCLC, as well as its effectiveness in patients with atypical EGFR mutations.

Asset Subtitle

Daniel Breadner

Meta Tag

Speaker Daniel Breadner

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

OCELOT study

osimertinib

third-line treatment

EGFR-mutated NSCLC

first-line treatment

second-line treatment

platinum-pemetrexed chemotherapy

efficacy

safety

atypical EGFR mutations